Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes

Key Points

• To evaluate the safety of GLP-1 and dual GLP-1/GIP receptor agonists during preconception, pregnancy, and lactation.
• Conducted a systematic review of existing literature
• Assessed maternal, fetal, and neonatal outcomes
• Focused on GLP-1-based therapies in early pregnancy
• No consistent evidence of increased maternal risk was found
• Fetal and neonatal risks appear minimal with early exposure
• Limited data exists on the safety of continued use throughout pregnancy